First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Cleveland Clinic oncologists’ selected abstracts
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Patients with a prior history of VTA are at an increased risk of subsequent incidents, despite treatment with therapeutic anticoagulation
Minimal residual disease testing shows promising results
Research indicates strong rationale for expanding trial eligibility criteria
A brief look at our programs
Preliminary trial reports positive patient response
Trial results point the way to further investigation